"All That Glitters is Not Gold…"* I n this issue of Critical Care Medicine, Lazaridis et al (1) describe the findings of a systematic review and metaanalysis, "23.4% saline in neurocritical care." In essence, the review found that in a broad range of acute brain injury syndromes, intracranial pressure (ICP) reduction was greater with hypertonic saline (HTS) 23.4% compared with mannitol (in most instances), at 60 mins or nadir. These data were reported in six studies from which this information could be extracted. Using a fixed-effects model, meta-analysis estimated that the percent decrease in ICP from baseline to either 60 mins or nadir after administration of 23.4% saline was 55.6% (se = 5.90, p < 0.0001, 95% confidence interval 43.99, 67.12).
This systematic review has assessed "disease-oriented evidence" as it evaluates a physiologic or surrogate marker of health. Improvements in these outcomes do not always lead to improvements in patient-oriented outcomes such as symptoms, morbidity, quality of life, or mortality. Therefore, these impressive se and confidence intervals should not be confused with an effect upon patient-orientated outcomes such as death or disability. Nonetheless, elevated intracranial pressure has consistently been associated with a poor outcome.
Although providing interesting information, the studies included in this systematic review differed by disease process studied and preinvestigation ICP reduction therapies (therapeutic intensity) before HTS administration. There was no standardization of pretreatment serum sodium. Theoretically, hypernatremia will reduce efficacy but may be less important with such concentrated sodium chloride solutions (2). The outcomes are described as percentage reduction compared with baseline. Selection bias for ICP reduction is likely in those studies that lacked allocation concealment and randomization. In many of the studies, equimolar hypertonic comparison is not made, making reliable conclusion about the efficacy of HTS difficult. However, the results are encouraging for HTS. ICP reduction was greatest with HTS, and there are limited but encouraging serious adverse event data. Of note are the MRI data specifically looking for central pontine myelinolysis in 18 patients (3), and 2 aneurismal subarachnoid hemorrhage patients had an autopsy to look for central pontine myelinolysis (4) .
I have some concerns about this systematic review. The results of any systematic review are more convincing if a priori research questions are published or put on a publicly accessible website such as PROSPERO (http://www.crd.york.ac.uk/ PROSPERO/), usually in the form of a protocol. This was not done in this case. The review is not systematic as there is no gray literature search, and I would have expected there to be some inaccessible papers. The flow sheet does not conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prisma-statement.org) guidance for systematic reviews, and there is absence of a measure of trial quality for each study.
Only Rockswold et al (5) and Paredes-Andrade et al (6) report mortality and other patient-orientated outcomes comparable with contemporary series. The remaining studies possibly examined HTS in the most severely damaged patients. It is not clear whether such results and recommendations can be applied to all acute brain injury syndrome patients.
Is magnitude of ICP reduction important and what are good surrogate markers in acute brain injury syndromes (7)? A surrogate marker should have a strong relationship with patientorientated endpoints such as improvement in symptoms, morbidity, quality of life, length of stay, or mortality. What is important is that the intervention improves functional recovery at 6 months and longer follow-up time points. It is of some concern, but understandable, that neurological intensivists become biased toward successful interventions to reduce ICP (and improvement in other short-term goals), despite any rigorous outcome data to support such a strategy. A search of trial registration Web sites show that only the Neurotherm3235Trial (Eurotherm in Europe) (8) is currently recruiting to a trial of ICP reduction with a patient-orientated primary endpoint, the extended Glasgow Outcome Scale. Successful ICP reduction in the Eurotherm3235 trial has challenged some recruiting centers equipoise, but completion of the trial is vital to confidently confirm benefit or harm of the intervention. Shakespeare is the best-known writer to have expressed the idea that "shiny things" aren't necessarily valuable or precious things. The original editions of The Merchant of Venice, 1596, have the line as "all that glisters (glitters) is not gold."
The bottom-line is we need patient-orientated evidence to support ICP reduction strategies in acute brain injury syndromes.
